Johnson & Johnson Robotics and Digital Solutions

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

<div>
 
 UK-based Enhanc3D Genomics is a functional genomics and bioinformatics company, developing novel diagnostic tools and therapeutic targets for cancer. The company has expanded its research to include other diseases, such as aging and autoimmune conditions.
 
 
 Its proprietary technology, called GeneLink3D, is an advanced mapping software that uses high-throughput sequencing and computational biology to generate a 3D structure of the genome.By doing so, it produces extensive datasets across various cell types. These datasets are then used to identify genetic interactions associated with diseases, including those that play a causal role in disease susceptibility and progression. Notably, the platform is capable of decoding the non-coding genome, presenting a promising avenue for discovering 100 new targets relevant to diagnostics and drug development.
 
 
 Funding and financials
 
 
 The company raised USD 11.2 million in October 2022 via a Series A financing round led by BGF and Parkwalk Advisors. The funds were allocated toward developing its platform GenLink3D and expanding its human capital.&nbsp;
 
 
 
</div>

<div>
 
 UK-based Nucleome Therapeutics is a biotechnology company focused on discovering novel treatment targets for diseases caused by genetic mutations starting with autoimmune disorders. Nucleome&rsquo;s cell type-specific platform uses AI to create high-resolution 3D genome structure maps and identifies genetic variations within the &ldquo;dark matter&rdquo; of the human genome. &quot;Dark matter&quot; refers to the majority of the genome that does not contain instructions for making proteins (non-coding regions of the genome). This part of the genome, although not well understood, is crucial for regulating genes and understanding diseases. It contains around 90% of the genetic changes associated with diseases.
 
 
 Funding and financials
 
 
 In October 2022, the company raised USD 41.9 million in a Series A funding round led by M Ventures (venture capital arm of Merck KGaA), with participation from new and existing investors, including Johnson and Johnson Innovation-JJDC, Inc., and Pfizer Ventures. The new funds were allocated toward advancing its drug candidates to treat autoimmune diseases and further expand its drug discovery platform. 
 
</div>

ONL Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for protecting and improving the vision of patients with retinal diseases. The company's primary focus is on advancing a breakthrough technology designed to protect key retinal cells from Fas-mediated cell death, which is the root cause of vision loss and blindness across various retinal conditions. ONL Therapeutics' lead product, ONL1204 Ophthalmic Solution, is a first-in-class small molecule Fas inhibitor designed as a neuroprotectant for key retinal cells, including photoreceptors.
ONL1204 is being developed for multiple retinal conditions. In February 2023, the US Food and Drug Administration (FDA) authorized the company to proceed with an Investigational New Drug (IND) application for ONL1204 Ophthalmic Solution. The company initiated a Phase 2 clinical study of ONL1204 in patients with macula-off rhegmatogenous retinal detachment (RRD) in the US in April 2023. This randomized, controlled study aims to enroll 135 patients across three arms, evaluating the safety and efficacy of a single intravitreal injection of ONL1204 as an adjunct to standard-of-care surgical repair.
In addition to RRD, ONL Therapeutics is conducting Phase 1 billion clinical trials for ONL1204 in patients with geographic atrophy (GA) associated with age-related macular degeneration (AMD) and progressing open-angle glaucoma in Australia and New Zealand. Preliminary results from the Phase 1 billion trial in GA associated with dry AMD showed promising outcomes, with patients treated with ONL1204 demonstrating reductions in the rate of growth of the GA lesion after six months of treatment compared to sham patients. The company is also exploring the potential of ONL1204 in other retinal conditions, including inherited retinal degeneration (IRD), also known as retinitis pigmentosa.
ONL Therapeutics is developing a platform of products for use in a wide range of blinding diseases, including retinal detachment, glaucoma, AMD, and IRD. The company's unique approach to preserving vision through Fas inhibition has the potential to address significant unmet medical needs in the field of ophthalmology.

<div>
 
 Artera is a precision medicine company that is working on AI tests with the aim of customizing treatment options for patients suffering from cancer, specifically prostate cancer. In 
 <a href="https://sp-edge.com/updates/19806">
 June 2023
 </a>
 , the company released data that validates the first-ever predictive AI biomarker for assessing the benefits of androgen deprivation therapy (ADT) in prostate cancer, which represents a significant advancement in the field of prostate cancer treatment. ADT is a treatment often used in combination with radiotherapy, but it is associated with known adverse effects.
 
 
 The company&rsquo;s flagship test is the ArteraAI Prostate Test, which is a test to identify patients who will benefit from therapy intensification and help guide treatment decisions for men with localized prostate cancer. The test is clinically available through a single CLIA-certified laboratory in Jacksonville, Florida and costs USD 3,873.
 
 
 Key Customers and Partnerships
 
 
 In April 2023, the company partnered with the 
 <a href="https://sp-edge.com/updates/17647">
 American Cancer Society
 </a>
 to improve outcomes and reverse disparities for Black men through its Improving Mortality from Prostate Cancer Together initiative, which focuses on using innovative technology to increase shared decision-making, treatment adherence, and reducing stigma in marginalized communities.
 
 
 Funding and Financials
 
 
 In February 2024, ArteraAI secured USD 20 million in a venture funding round, which saw participation from Prosperity7 Ventures, EDBI, Walden Catalyst Ventures, Wilson Sonsini Goodrich &amp; Rosati, and other investors. The company intended to use the funds to back its international expansion and support its commercial growth and testing services. 
 
</div>

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

HistoSonics is a medical device company that develops non-invasive platforms utilizing histotripsy, a novel focused ultrasound therapy. The company's primary product is the Edison Histotripsy System, which received FDA De Novo clearance in October 2023 for the non-invasive destruction of liver tumors. Histotripsy uses focused sound energy to produce controlled acoustic cavitation that mechanically destroys and liquefies targeted tissue at sub-cellular levels without damaging surrounding healthy tissue. The Edison System combines proprietary technology with advanced imaging to deliver personalized, non-invasive treatments with precision and control. It allows physicians to monitor tissue destruction in real-time, offering visualization and control not available with existing modalities. The system achieved a 95.5% technical success rate in clinical trials for precisely targeting and destroying liver tumors. HistoSonics is currently focused on commercializing the Edison System for liver treatments in the US and select global markets while exploring expanded applications for histotripsy in other organs such as the kidney, pancreas, and prostate.
Key customers and partnerships
HistoSonics has partnered with leading institutions across the US and internationally to develop multi-disciplinary histotripsy liver programs. The company conducted clinical trials at 13 sites across the US and Europe, including Mutua Terrassa Hospital and Vall D'Hebron Hospital in Barcelona, Spain. HistoSonics also maintains research collaborations with the University of Michigan, where histotripsy was originally developed, and the University of Wisconsin, which provides critical product development capabilities and validation of the company's non-invasive approach across multiple applications. In August 2024, HistoSonics announced plans to initiate the BOOMBOX Master Study to further evaluate the Edison System for liver tumor treatment across multidisciplinary users.

V-Wave focuses on developing interatrial shunt devices for treating heart failure (HF). Its flagship product, the Ventura Interatrial Shunt, is an investigational device designed in an hourglass shape to reduce elevated left atrial pressure, a key driver of pulmonary congestion and hospitalizations in HF patients. The shunt creates a controlled amount of blood flow between the left and right atria, lowering left atrial pressure while protecting the right heart from volume overload. It is implanted through a minimally invasive catheter-based procedure, with patients typically discharged after an overnight stay.The Ventura Shunt has received breakthrough device designation from the FDA and CE Marking in the EU. As of July 2024, V-Wave was undergoing trial and was yet to obtain FDA approval. In April 2024, V-Wave announced positive results from its RELIEVE-HF trial.

Moon Surgical is a surgical robotics company that developed the Maestro Robotic System. It's a robotic surgical assistant designed to enhance traditional laparoscopic techniques. The Maestro System comprises two flexible robotic arms that can hold and manipulate laparoscopic cameras, probes, and instruments during soft-tissue surgical procedures.The key differentiator of the Maestro System is its ability to seamlessly integrate into existing clinical workflows without disrupting the surgeon's conventional laparoscopic techniques or requiring specialized training. It acts as an extension of the surgeon's hands, providing an extra set of arms that can be controlled manually or operated autonomously through computer vision and AI. This system aims to improve operating room efficiency, reduce procedure duration, and enable alternative labor models, ultimately enhancing the surgical experience.In December 2022, Moon Surgical received FDA clearance for the Maestro System, allowing select high-volume surgical centers in the US to access its capabilities. In June 2024, Moon Surgical received a second FDA clearance for the commercial version of the Maestro System, paving the way for a limited market release in the US and Europe ahead of a broader launch in 2025.Key customers and partnershipsMoon Surgical primarily offers the Maestro Robotic System to surgical centers. Moon Surgical has collaborated with NVIDIA to integrate the NVIDIA Holoscan Edge computing platform into the Maestro System, enabling real-time AI algorithms for features like the ScoPilot hands-free laparoscope control. As of March 2024, the Maestro System, integrated with NVIDIA Holoscan, has successfully treated over 200 patients across various surgical procedures. Its first clinical use in the US was by three surgeons who practice at Baptist Health hospitals.

Prana Thoracic, a medical device startup based in Houston, is dedicated to developing solutions for early intervention in lung cancer. The company is working on the ThoraCore System, a minimally invasive, lung-sparing device designed for the excision of targeted lung tissue. This electrosurgical instrument utilizes a specialized anchor to target lung nodules under computed tomography guidance, employing bipolar radiofrequency to seal the incision and minimize bleeding and air leaks.
The ThoraCore System aims to address the limitations of current lung cancer screening methods, which often fail to provide definitive diagnoses. Needle biopsies are ineffective for smaller nodules, while invasive surgeries carry significant risks and complications. By enabling minimally invasive tissue extraction, ThoraCore promises to facilitate earlier and more accurate diagnoses, leading to improved treatment outcomes for lung cancer patients.
Lung cancer is the leading cause of cancer-related deaths in the US, accounting for nearly 25% of all cancer deaths. While over 14 million patients are eligible for lung cancer screening annually, less than 5% undergo the procedure. Prana Thoracic's technology aims to bridge this gap, providing physicians with a tool to intervene earlier in the patient's journey.
In March 2023, Prana Thoracic announced the closing of a USD 3 million Series A financing round led by New World Angels, joined by Johnson & Johnson Innovation, Texas Medical Center Venture Fund, and the University City Science Center's Phase one Ventures. Additionally, the company received a USD 3 million award from the Cancer Prevention & Research Institute of Texas (CPRIT) in August 2022. These funds will support the development of ThoraCore and the company's first-in-human clinical studies.

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

Welldoc offers a chronic care platform supporting various conditions such as prediabetes, diabetes, hypertension, heart failure, weight management, mental well-being, and sleep apnea. Welldoc's FDA-cleared digital health app, BlueStar, assists individuals in self-managing their diabetes care and strengthens their connections with their healthcare team. The company offers holistic guidance to assist individuals in managing their daily nutrition, physical activity, data tracking, and long-term trends.In August 2023, the company was the first to receive FDA approval to provide bolus insulin dose recommendations based on continuous glucose monitoring (CGM) readings, and, as of May 2024, the company held 11 FDA clearances and 43 patents for advanced AI and technology and was included in more than 80 clinical publications.Key customers and partnershipsTo expand its solutions, the company has partnered with pharmacy benefit managers, health plans, health systems, and employers, including 1) Dexcom, provider of a CGM system, to offer integrated type 2 diabetes management solutions (in April 2021), 2) LifeScan, a blood glucose monitoring provider, to incorporate Welldoc’s platform into LifeScan’s OneTouch Solutions for diabetes management (in September 2021), and 3) Conifer Health Solutions, a Johnson &amp; Johnson company producing blood glucose meters, to launch a health app called Conifer Connect (in April 2023).Funding and financialsIn March 2016, the company raised USD 29.5 million in a Series B round led by Samsung Ventures, Johnson &amp; Johnson Robotics, and Digital Solutions. The funds were used for commercialization of its BlueStar solution.

The intersection of beauty and technology to deliver hyper-personalized products.

Beauty Tech

<div>
 
 EpigenCare is a personalized skincare platform that recommends products based on skin attributes through DNA analysis. It provides customers an at-home kit named &ldquo;Skintelli'' to non-invasively collect samples to check DNA methylation levels. The company generates revenue through outright sales of its skincare tests, with prices ranging from USD 49.99 to USD 399.00.
 
 
 The company claims to have identified a proprietary panel of genes that strongly correlate with changes to major skin conditions such as aging, moisture, and elasticity. The company also developed an algorithm to screen product ingredients to determine the best products in the market for each individual to reverse or slow-down the negative effect of genetics.&nbsp;
 
 
 The company launched a beta version in February 2019 and an early access kit was available as of November 2023.
 
 
 Key customers and partnerships
 
 
 In March 2018, EpiGentek, a biotechnology firm specializing in epigenetic research products and services, partnered with EpigenCare to offer technological and financial support to accelerate the commercialization of EpigenCare&rsquo;s personalized skincare tests.
 
 
 
</div>

AI-based solutions for evolving digital threats

Next-gen Cybersecurity

<div>
 
 MedCrypt is a Y Combinator incubated medical device startup that provides proactive cybersecurity solutions to secure connected medical devices such as glucose monitors, surgical robots, insulin pumps, heart rate monitors, AI-based radiology tools, and autonomous robots from cyber attacks. The platform provides cryptographic communication, behavior monitoring, and vulnerability monitoring and management to secure these devices. It ensures that devices act only according to instructions from trusted sources and provides an early warning system against intrusions with an event monitoring system that detects anomalous behavior. The company provides solutions to monitor devices in the field, secure existing and new devices, and monitor software bill of materials (SBOM) for known vulnerabilities.
 
 
 MedCrypt-enabled devices transmit healthcare-specific behavior metadata to Canary, an event monitoring system, which allows users to monitor and assess the behavior of devices in the field to detect security events, generating alerts to abnormal behavior in real time. Ghost is a secure overlay agent that enables encryption on existing devices. Guardian is an embedded library that provides cryptography functions such as signature verification and data encryption via an API/ABI. This allows users to sign code, data, instructions, configurations, and more and verify data structures before loading into an active device, whilst ensuring privacy. Heimdall, which is a vulnerability management tool, imports SBOMs and monitors for vulnerabilities.
 
 
 MedCrypt has an employee headcount of more than 20. As of November 2022, the company had plans to go public.
 
 
 Key customers and partnerships
 
 
 In 2022, MedCrypt partnered with 18 new medical device manufacturers and it served seven of the top 10 medical device manufacturers, as of January 2023. Notable customers include Tenac.io and Qlife.
 
 
 Funding and financials
 
 
 In November 2022, the company 
 <a href="https://sp-edge.com/updates/14188">
 raised USD 25 million 
 </a>
 in a Series B funding round, co-led by Intuitive Ventures and Johnson &amp; Johnson Innovation. The funds were utilized to expand its cryptography, behavior monitoring, and vulnerability inventory products across different types of medical devices and to grow its engineering team.
 
 
 In January 2023, the company 
 <a href="https://sp-edge.com/updates/15956">
 raised an undisclosed sum
 </a>
 as an extension to its Series B funding round from Dexcom Ventures. The funds were utilized to grow its engineering team.
 
</div>

Reinventing gene therapies with next-generation technologies

Human Gene Editing

<div>
 
 Locus Biosciences specializes in CRISPR-based gene editing to develop novel anti-bacterial and engineered phage therapies to address a variety of therapeutic areas including infectious diseases, oncology, and immunology. It uses its proprietary platform, which entails bacteriophage discovery, synthetic biology, and manufacturing capabilities.&nbsp;
 
 
 The company&rsquo;s approach uses CRISPR-Cas3-enhanced bacteriophage (crPhage) to precisely target the unwanted bacteria and deliver Type-1 Cas3 enzymes to delete undesirable genetic material or DNA, thereby eliminating the bacteria. It had five drug development programs in its pipeline of which one&mdash;targeting urinary tract infections&mdash;was in the clinical stage, scheduled to initiate Phase II/III clinical trials in mid-2022. Locus also has four other research programs for various disease indications including inflammatory bowel disease (IBD).&nbsp;
 
 
 Key customers and partnerships
 
 
 Locus offers its platform to biotechnology and pharmaceutical companies to develop novel therapeutics and also supports its partners throughout the drug development process, including the manufacturing and clinical stages. It entered into a research collaboration and licensing agreement with 
 <a href="https://www.prnewswire.com/news-releases/locus-biosciences-enters-a-collaboration-and-license-agreement-with-johnson--johnson-innovation-to-develop-crispr-cas3-bacteriophage-therapeutics-300771975.html">
 Janssen Pharmaceuticals
 </a>
 in January 2019 to discover, develop, and commercialize crPhage. In June 2022 , Locus partnered with 
 <a href="https://www.prnewswire.com/news-releases/cosmosid-announces-microbiome-partnership-with-locus-biosciences-to-provide-long-term-clinical-trial-support-301571492.html">
 CosmosID
 </a>
 to obtain clinical trial support from the latter.&nbsp;
 
 
 Funding and financials
 
 
 In January 2024, Locus Biosciences raised USD 23.9 million in funding from the Biomedical Advanced Research and Development Authority (BARDA). The funding was set aside to advance the second part of its ELIMINATE Phase II trial involving LBP-EC01, a therapy aimed at treating urinary tract infections (UTIs) caused by drug-resistant Escherichia coli (E. coli). The financial boost was part of a larger USD 85 million contract with BARDA originally signed in September 2020. The total funds released to date under this contract were USD 48.9 million.
 
</div>

Additive manufacturing makes objects by systematically adding material via a CAD program

Additive Manufacturing

Carbon sells 3D printers along with related software and material for additive manufacturing to allow mass customization and on-demand inventory management. With a range of patented engineering and dental resins, Carbon targets automotive, consumer goods, dental (healthcare), and other industrial use cases. Carbon’s product portfolio includes several types of 3D printers named M1, M2, and M3 (an advanced end-to-end idea-to-production platform introduced in January 2022) as well as L1 and a parts washer. Carbon’s materials portfolio includes rigid, elastomeric, and dental materials. Carbon’s design software platform was launched targeting product designers globally in 2022. It offers regular software updates to its printers to continuously improve the processes and the outcome. With the acquisition of design software company <a href="https://sp-edge.com/updates/12722">ParaMatters </a>in August 2022, Carbon expanded its software capabilities to include topology optimization capabilities, allowing users to speed up the design iteration process and create complex, high-performance part designs.The company also offers print analytics solutions, allowing real-time review of production data and part traceability from design to print stage. Adding to its proprietary pool of materials, in February 2022, Carbon introduced a flame retardant photopolymer resin that ensures durability and the long-term stability of printed parts.Carbon uses patented Digital Light Synthesis (DLS) technology that uses digital light projection and engineering-grade materials to develop parts with mechanical properties and a surface finish. DLS is driven by Carbon’s Continuous Liquid Interface Production (CLIP) technology, which uses ultraviolet (UV) light to cure liquid plastic resin into solid parts. Unlike traditional resin-based 3D printing (which reportedly makes weak parts), Carbon’s printed parts are baked in an oven, exposing the parts to a second heat-activated programmable procedure for improved strength.&nbsp;In November 2024, the company&nbsp;<a href="https://sp-edge.com/updates/36173">launched the EPU Pro platform</a>, a single-part, dual-cure elastomer resin. EPU Pro offers a range of stiffness options with durometers from 50A to 90A. It incorporates foaming agents for suede-like textures and features enhanced printability for complex geometries.Key customers and partnershipsCarbon had a presence in 17 countries as of January 2024, with plans to expand to other international markets in the future. The company also operates through a network of design firms and contract manufacturers that specialize in Carbon’s technologies. Carbon connects customers with these partners if they have a prototype that needs to be made.Carbon has entered several partnerships with other AM companies including Desktop Metal to bring its Flexcera resins to the Carbon Digital Manufacturing Platform (July 2023), Henkel to combine materials and printing expertise (October 2020), and Shapeways to offer access to Carbon’s 3D printing technology and materials (March 2019).Funding and financialsIn June 2019, Carbon raised USD 260 million co-led by Madrone Capital Partners and Baillie Gifford, bringing the company’s total funding to USD 683.4 million. Carbon planned to use this capital to expand R&amp;D, establish its first advanced development facility (ADF), and support international growth in Europe and Asia.&nbsp;

Targeting complex diseases with complex molecules

Large-molecule Therapeutics

DJS Antibodies was a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines targeting difficult-to-drug proteins, such as G protein-coupled receptors (GPCRs). Its lead program was DJS-002, a potential first-in-class lysophosphatidic acid (LPA) receptor one (LPAR1) antagonist antibody in investigational preclinical studies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases as of October 2022. IPF is an aggressive, high mortality disease caused by fibrotic scarring in the lungs.
DJS Antibodies' proprietary HEPTAD platform was a novel approach to antibody discovery with specific capabilities targeting transmembrane protein targets like GPCRs, which were previously intractable to biologics approaches. In October 2022, AbbVie acquired DJS Antibodies for approximately USD 255 million in cash at closing, with the potential for additional payments upon achieving certain development milestones related to the DJS-002 program. Through this acquisition, AbbVie gained access to the HEPTAD platform to complement its existing biotherapeutics research capabilities. DJS Antibodies was anticipated to leverage AbbVie's drug discovery expertise to continue generating antibody therapeutics and novel biology insights against targets such as GPCRs.

Redefining hospital care with the comfort of home

Hospital-at-Home

Binx Health is a healthcare technology and diagnostics company focused on expanding access to convenient and equitable healthcare through innovative testing solutions. The company's primary offering is the Binx io, an FDA-cleared, CLIA-waived point-of-care molecular platform for rapid diagnosis of chlamydia and gonorrhea. This system can deliver results in about 30 minutes, enabling same-visit diagnosis and treatment in various clinical settings such as doctors' offices, urgent care clinics, and hospital emergency rooms. The Binx io platform is designed to be highly flexible and easy to use, collapsing the time between testing and treatment while the patient is still in the clinic.
In addition to its point-of-care testing, Binx Health previously operated a consumer testing business that provided at-home testing services for various health conditions. However, in December 2023, this division was sold to Imaware, allowing Binx to focus solely on its point-of-care offerings. The company's technology aims to address the growing epidemic of sexually transmitted infections (STIs) by providing rapid, accurate testing that can lead to immediate treatment and potentially reduce infection spread.
Binx Health has established partnerships with major medical device distributors, including Cardinal Health, Fisher healthcare, McKesson, and Medline, to broaden its market reach. The company has also worked with state governments, including North Carolina and Maryland, to provide Covid-19 testing solutions during the pandemic. As of April 2024, Binx Health secured USD 65 million in series F financing to support its commercial growth and manufacturing scale. The company is actively expanding its testing capabilities, with plans to develop point-of-care diagnosis for trichomoniasis in the future.

Therapeutics that target specific areas/tissues to minimize treatment side effects.

Tissue Targeting Therapeutics

Aro Biotherapeutics is a clinical-stage biotechnology company based in Philadelphia that specializes in developing tissue-targeted genetic medicines. The company's core technology is a proprietary protein platform called Centyrins, which enables efficient and tissue-specific delivery of siRNA and other genetic drugs. Aro's lead candidate, ABX1100, is being developed for the treatment of Pompe disease, a rare genetic disorder characterized by toxic glycogen accumulation in muscles. ABX1100 comprises a CD71 receptor-binding Centyrin conjugated to a small interfering RNA (siRNA) that targets the Gys1 gene, reducing levels and activity of the Gys1 enzyme in muscle tissues. The therapy has shown promising results in preclinical studies, demonstrating potent and muscle-specific reductions in Gys1 mRNA and protein in the Pompe mouse model. In October 2023, Aro initiated a Phase 1 clinical trial of ABX1100 in Canada, with initial data expected in 2024. The US Food and Drug Administration granted ABX1100 Orphan Drug Designation and Rare Pediatric Disease status. Beyond Pompe disease, Aro is exploring the potential of its Centyrin-siRNA conjugate programs for developing new treatments for autoimmune disorders.

TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us to identify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis.

Moon Surgical is a medical device company developing a surgical robot for laparoscopy assistance. MastOR is an early-stage surgical robotics company whose laparoscopy assistance platform broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room. The Maestro System from Moon Surgical, provides complete control, fresh trust, and technology that can adapt to every condition faced, resulting in increased operating room efficiency and surgical care for patients. Moon Surgica is employing tomorrow's technology to alter surgery today.

Manus Neurodynamica is a triage device to support early diagnostics in Parkinson's disease.

Glyphic Biotechnologies is a biotechnology company that develops a protein sequencing platform. While DNA can reveal biological insights, proteins provide the actual insights into the functions of our bodies. The company is in the process of developing a pioneering, next-generation protein sequencing platform that will empower researchers to acquire unprecedented insights into both biology and diseases.

Artera develops medical artificial intelligence tests that personalize therapy for cancer patients. Its tests predict therapeutic benefits and prognosticate patient outcomes. The Artera platform is purely software, and runs on digital images of H&E histopathology images as part of routine clinical care.

ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. It was founded in 2011 and is headquartered in Ann Arbor, Michigan.

AmacaThera is a clinical-stage biotechnology company developing a novel drug delivery platform to improve patient outcomes across multiple therapeutic areas, including post‑surgical pain management, cancer, and other hard‑to‑reach target areas. AmacaThera is developing combination products at the interface of biomaterials and pharmaceuticals.

MedCrypt is a medical device company that provides data security as a service to medical device OEMs. From medical imaging device to implantable devices like pacemakers, MedCrypt ensures that devices act only on instructions from trusted sources. It brings security features to medical devices, from pacemakers to surgical robots, in a few lines of code. The company enables engineers to implement these security features properly as quickly as possible, allowing them to get back to designing life-changing clinical features. MedCrypt was founded in 2016 and is headquartered in Encinitas, California, United States.

Houston-based medical device startup Prana Thoracic, Inc. is dedicated to developing solutions for early intervention in lung cancer. We are an experienced team of surgeons, engineers and entrepreneurs on a mission to tackle lung cancer; the #1 cancer killer in the US. The paradigm of screening, detection, and early intervention that has been deployed in other major cancers has so far eluded lung cancer. As a result, only 16% of lung cancers are found at an early stage and the current 5-year survival rate is < 20%. Recent changes to lung cancer screening guidelines have illuminated a path to improving outcomes in lung cancer. However, these advances rely on excising suspicious nodules and providing sufficient tissue for definitive diagnosis. We believe this is the missing piece of the puzzle, and physicians need a new generation of surgical oncology tools for lung cancer. Prana Thoracic plans to revolutionize the early diagnosis and treatment of lung cancer by making it easier and less invasive to deal with the rapidly growing number of early suspicious lung nodules; ensuring that we do not miss the window of opportunity to intervene early.

Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat disease. The dark genome holds more than 95% of disease-linked genetic variants whose value remains untapped, representing a significant opportunity for drug discovery and development. We have the unique ability to link these variants to gene function and map disease pathways. Our cell type-specific platform creates high resolution 3D genome structure maps and enables variant functional validation at scale in primary cell types. This enables us to discover and develop novel, better and safer drugs. The initial focus of the company is on lymphocytes and related autoimmune disease. Our ambition is to build a robust pipeline of drug assets, with corresponding biomarkers. Nucleome Therapeutics was founded by leading experts in gene regulation from the University of Oxford and backed by investment from Oxford Sciences Innovation. For more information, please visit www.nucleome.com.

Cara Care is a digital gut health platform that offers an app-based treatment to help patients with chronic gastrointestinal problems. It empowers patients suffering from chronic digestive diseases to enjoy a better life. Cara Care takes digestive health beyond the pill, bringing together behavioral, microbial, and nutritional data. Cara Care has already helped 700.000+ patients around the world with software-based medical devices.

Enhanc3D Genomics is a functional genomics firm that studies the three-dimensional organization of DNA in health and disease. The company's GenLink3D platform helps comprehend the impact of such mutations on distant genes, thereby revealing how they influence disease progression.

Locus Biosciences is a developer of a CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease. The company's platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses called bacteriophage, enabling physicians to begin treatment more quickly, resulting in a better medical outcome.

IndyGeneUS AI is a Black-Owned & Service-Disabled Veteran-Owned Small Business (SDVOSB) genomics company creating the world’s largest digital blockchain-encrypted repository of indigenous and diasporic African clinical and genomic data. Our proprietary technology can detect novel signature sequences, biomarkers, and polygenic risk scores by integrating “multi-omics” data, electronic healthcare record (EHR) data, and textual information such as scientific manuscripts.

Viora Health (www.viorahealth.com) is a health and wellness company whose mission is to empower diverse populations to advance health equity. Our tech-enabled human-centered programs use social and behavioral engagement to improve capacity, satisfaction, outcomes, and revenue for providers. Our work is funded by the American Heart Association (AHA) and the National Institutes of Health (NIH) and Johnson and Johnson (J&J) and the National Science Foundation (NSF) and validated using an IRB approved study. Our programs have achieved 75% satisfaction score  with 2x retention, and improved outcomes (lower stress, improved activation, social support, and food access).

On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010 and is based in Northbrook, Illinois.

Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action. Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids.

DERMALA is a consumer dermatology company leveraging scientific understanding of the human microbiome and data analytics to develop personalized, clinically validated, patented treatments for chronic skin conditions including acne and eczema. The company’s #FOBO® (Fear of Breaking Out) system, a personalized microbiome-based solution for acne, combines patented topical acne treatments and oral supplements with a proprietary DERMALA Acne Tracker app that customers use to track their skin health and get their treatment optimized monthly. For more information, visit dermala.com.

XW Laboratories is an Asia-Pacific biopharmaceutical company dedicated to discovering and developing transformational medicines that will markedly improve the quality of life in patients suffering from neurological disorders. Founded in 2014, XW Laboratories has developed 3 unique drug R&D platforms that not only allow us to improve upon existing medication through approaches such as prodrug and functional group switch, but also be at the forefront of medicinal technology in immunoneurology through the application of their mitochondria-targeting platform.

2 out of 3 men will start to lose their hair by the age of 35 - but the earlier you take action, the more hair you keep. Keeps is a full-service healthcare company focused exclusively on helping men keep their hair. From expert diagnosis to affordable treatment, patient support to education, Keeps provides a regimen specific to each customer's condition through a seamless digital experience, allowing men to manage hair loss from start to finish. Keeps’ licensed physicians review each customer's information in order to identify and prescribe a unique treatment plan of FDA-approved products, and we sell them at half the price customers would pay at their local pharmacy. With Keeps, customers receive exactly what they need, and nothing they don’t. Keeps is the first brand from Thirty Madison, which is rebuilding the healthcare experience for the modern consumer.

Legend Biotech is a clinical-stage biopharmaceutical company that discovers and develops novel cell therapies for oncology. The company develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. Its initial product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma.

Adicet Bio is a biotechnology company engaged in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.

Carbon provides printing solutions for products that outperform. The company helps businesses develop better products and bring them to market in less time. Carbon is a venture-backed company. They serve industries including automotive, consumer, industrial, life sciences, and dental.

Artizan Biosciences provides pharmaceutical drug development services, namely, the development of small molecule drugs for use in humans. The Durham-based biotech company declined to disclose its intended use of the proceeds from this offering, as well as its current revenue range.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

Hyalex Orthopaedics is a Lexington, MA medical device company advancing new products that feature HYALEX™ materials technology, a polymer that is designed to mimic cartilage. Unlike other polymers, synthetic HYALEX material has the unique capability of maintaining low friction and low wear under the high loads encountered in human joints.  Hyalex Orthopaedics' products are in the development stage and have not been approved for use in humans by any regulatory agency.

Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients. Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient’s cell-free, circulating tumor DNA (ctDNA) which can be collected through a simple blood sample. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored, and treated.

BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators: Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology.

Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.A highly experienced management team with strong expertise in drug development and an extensive scientific and industry network manages Calypso Biotech. They operate as a nimble, semi-virtual organization in order to create substantial added value for their investors from a portfolio of unique proprietary antibody candidates.

Bsense Bio Therapeutics develops small molecules for the treatment of sensory hyperexcitability related disorders. Bsense pioneers a novel approach targeting multiple hyperexcitability-related mechanisms using a single compound, to achieve greater efficacy and safety.

Ramino Bio is a private biotech company that develops an oral drug to treat metabolic diseases. Ramino has received funding totaling about $3.3 million since its beginning from the FutuRx biotech incubator, which is supported by the Israeli Innovation Authority, Takeda, J&J, OrbiMed, and RMPG. By speeding up their disintegration, our exclusive technology lowers the extra BCAA that is floating around.

Magnolia Neurosciences aims to discover and develop proprietary, selective, and drug-like small molecule therapeutics for the prevention of neuronal cell death, thereby providing novel treatment options for patients suffering from neurodegeneration and related conditions. Magnolia Neurosciences Corporation, created to pursue technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium (NDC), is a New York-based Accelerator Life Science Partner portfolio company.

V-Wave is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with Chronic Heart Failure (HF). V-Wave’s vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment. V-Wave has developed a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity, and improve the overall quality of life. The original concept and development started in Israel with a talented team of engineers and medical scientists. The company’s senior management has decades of experience successfully developing, clinically testing, and bringing to market multiple implantable cardiovascular devices.

Osteal Therapeutics is a clinical-stage specialty pharmaceutical company developing novel drug and device combination products for treating musculoskeletal infection.

RefleXion is developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT),  stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency.

EpigenCare is connecting consumers with skincare companies through a direct-to-consumer skincare test and web platform on the Ethereum network.  Consumers receive actionable recommendations of optimized skincare products to use, as well as assess the progress of their skincare routines, based on their skin's epigenetic profiles. The recommendation engine looks at the functional state of a panel of epigenetic markers strongly correlated with skin quality indicators (e.g., aging, moisture retention, elasticity, etc.), and how skincare product ingredients affect them. It offers SKINTELLI, a direct-to-consumer personal epigenomics test that measures DNA methylation levels of a proprietary panel of genes responsible for key skin quality factors (e.g., aging, elasticity, moisture retention, etc.). The SKINTELLI web platform empowers you with the knowledge of which products truly work for your skin.  EpigenCare was founded in 2017 and based in Farmingdale, New York.

Certa Dose is a medical device company that offers an intuitive system that uses color confirmation to deliver accurate dosing. Its first product is a U.S. Food and Drug Administration-cleared syringe for use with the administration of epinephrine to pediatric patients. Each syringe is labeled with easy to recognize color zones that match the industry-standard Broselow pediatric color-coding system to help clinicians verify the correct dose during critical, time-sensitive situations. Users match the patient to a zone on the color scale and administer the medication to the corresponding color on the Certa Dose syringe. The patented syringe incorporates the right dose, the right concentration, and the right route of administration of medication dosing, along with a color-matching technology that creates an easy-to-use system focused on saving children’s lives by curbing critical medication errors

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company. It is a spinout of the Centre for Probe Development and Commercialization (CPDC), a leading radiopharmaceutical research and GMP production center. Fusion’s deep radiochemistry expertise presents a technology platform that can be replicated to turn internalizing antibodies that have previously demonstrated limited clinical efficacy into highly effective cytotoxic drugs. Fusion’s ability to link effective isotopes to the targeting antibody allows for the creation of optimized agents for both diagnostic imaging and radioimmunotherapy (Precision Medicine). Following positive tumor identification with the imaging agent, treatment with the antibody linked to a therapeutic isotope delivers a cytotoxic payload into the cancer cell. Fusion’s lead product candidate, FPX-01, is a precision RIT that is a product of this innovative approach. FPX-01 has been designed to internalize targeted cancer cells and deliver a lethal and highly localized radioactive payload. The precise targeting of this radiolabeled antibody causes selective and extremely effective cytotoxicity of tumor cells at relatively low doses of radioactivity.

Rodeo Therapeutics is a drug development company focused on novel enzyme target and biological pathway that play a critical role in tissue repair and regeneration.  Rodeo’s initial goal is to develop novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant.

Escape Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases. The company is developing therapeutics for the novel, precisely therapies for genetic neurodegenerative diseases.  Escape Bio's pipeline includes candidates targeting known genetic drivers of multiple diseases, including ESB1609, a small molecule S1P5 receptor agonist for the treatment of CNS lysosomal storage disorders and ESB5070, a small molecule kinase inhibitor for Parkinson’s disease patients who have an LRRK2 G2019S variant and an Alzheimer's disease program targeting ApoE4.  E-scape Bio was founded in 2015 and is headquartered in San Francisco, California, United States.

The SuperX team is engaged in the discovery of antibodies against an undisclosed target in the blood coagulation cascade.  SuperX hopes to reach the clinic in 2019.A preclinical stage biopharmaceutical company, based at Babraham Research Campus, developing novel anticoagulant drugs

Provention Bio is a clinical-stage biopharmaceutical company dedicated to sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease. Their predict and prevent model is focused on developing novel therapeutic approaches that intervene before the target disease begins, re-appears, or progresses.  Provention Bio offers the potential to reduce the high morbidity, mortality, patient suffering, and escalating costs of chronic autoimmune and inflammatory diseases, such as type 1 diabetes (T1D), Crohn’s disease, ulcerative colitis, and emerging viral infections. They believe Provention’s business model, coupled with its expertise in translational medicine, immunology, and the design and execution of rapid go/no-go clinical trials, will enable them to in-license and efficiently partner both early-stage development assets and more advanced clinical-stage opportunities.

Binx Health is committed to broadening convenient and equitable access to healthcare. The company's point-of-care diagnostic solutions empower its partners to overcome traditional barriers to care, extend their outreach, and deliver exceptional patient experiences. The binx io point-of-care molecular platform marks a significant milestone as the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males (urine) and females (vaginal swabs). It delivers results comparable to those of central lab performance, typically within about thirty minutes.

ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapies eventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.

OrthoSpace develops and commercializes simple-to-implant, biodegradable balloon systems for the orthopaedic market. The company aims to create effective solutions for orthopaedics that reduce pain and increase patients’ range of motion while preserving patient bone and joint structures.  The company’s first product has the CE mark and is currently marketed in Europe. InSpace™ is indicated for patients who suffer from rotator cuff injury, reducing shoulder pain and improving range of motion.

Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway.  The company's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathways in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it.  It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel.

BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development, shares in the cost and risk of clinical development, and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States.

Torax Medical, Inc., a clinical stage medical device company, develops an implantable device for the treatment of gastroesophageal reflux disease. It provides treatments for digestive diseases, including acid reflux. The company was founded in 2002 and is based in Shoreview, Minnesota.

Welldoc develops technology solutions to support chronic disease management. They work with leaders across the healthcare, life science, and medical device industries to ensure the solutions they develop scale and integrate into their existing workflows and systems. The Welldoc platform offers support for multiple chronic conditions, ecosystem solutions, and artificial intelligence.

Lodo Therapeutics Corporation is a drug discovery and development company focused on the creation of naturally derived novel therapeutics that will have a dramatic impact human health on a global basis. Lodo seeks to work in partnership with global pharmaceutical companies and world leading Non-Governmental Organizations (NGO’s) to tackle some of the greatest challenges in human health:  resistant infectious disease and cancers.   Lodo Therapeutics was created to pursue the scientific vision of Dr. Sean Brady at Rockefeller University. Dr. Brady and his laboratory have developed a genome-based, culture-independent platform for the discovery, biosynthesis, and characterization of small molecules from microbial sources present in soil samples.  Lodo believes that the potential cures for a number of deadly and/or debilitating diseases literally lie at our feet. By combining the advancements in DNA sequencing and bioinformatics, this innovative discovery platform exploits the power of microbial evolution for the identification of therapeutically valuable pharmaceutical products derived from natural sources.   Lodo Therapeutics, an Accelerator Corporation-backed entity, is headquartered in New York City.   The company’s lab and offices are located in the Alexandria Center for Life Science, New York City’s first and only premier life science park.

Aelix Therapeutics develops therapeutic vaccines and immunotherapies to treat HIV infection. The company is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV.   The company was created under the leadership of its founders, Dr. Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Mr. Jordi Naval; all of whom have several decades of experience in HIV and biotech development. The company’s know-how will further expand through unique immunogen designs. It will also benefit from ready access to large cohorts of HIV infected patients in several continents through its partnership with the HIVACAT consortium.

Petra Pharma is a clinical-stage pharmaceutical company developing a diverse portfolio of novel therapies for serious medical conditions such as cancer and metabolic diseases. The company also focused on novel enzyme targets that play a central role in a variety of important cellular processes, including cell division, growth, trafficking, and signaling. It will develop novel small molecules for the treatment of cancer and metabolic diseases to target these cellular processes in order to therapeutically impact human health. Petra Pharma was founded in 2016 and is headquartered in New York, USA.

Navitor Pharmaceuticals is a developer of novel medicines designed to target specific nutrient-sensing proteins that selectively regulate mTORC1 activity to treat diseases. The company's medicines selectively modulate the activity of mTORC1, a master regulator of cell growth and metabolism, and unlock the therapeutic potential of the mTOR pathway by targeting the amino acid and other nutrient sensors that selectively regulate the activity of mTORC1, enabling healthcare practitioners to address a wide range of metabolic, neurodegenerative, autoimmune and musculoskeletal diseases. It was founded in 2009 and headquartered in Cambridge, Massachusetts.

First Aid Shot Therapy offers a market segment defined as clinical beverages designed to address acute or chronic clinical needs. It offers a range of easy-to-swallow, single-dose products that provide fast-acting relief for most common everyday symptoms; hangover, pain, sleep, cold, allergy, and heartburn. The company was founded in 2010 and is headquartered in Burlingame, California.

PrEP Biopharm is a biopharmaceutical company. That focused on the prevention of respiratory infections. They prevent upper respiratory tract viral infections. PrEP-001 is a phase 2 nasal spray that increases the host's innate immune response and protects against all respiratory viruses and is predicted to be used to combat respiratory viral pandemics such as COVID-19.

Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.  Tauopathies are currently untreatable neurodegenerative diseases that rapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).  Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.

Merus B.V., a biomedical company, engages in the discovery and development of antibody-based biopharmaceuticals. It develops Oligoclonics technology that offers a class of human antibodies called Oligoclonics. Oligoclonics is a concept whereby a mixture of various human therapeutic antibodies, directed to a common antigen are produced from a single cell clone.

Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options and a patient-centric focus. Leveraging extensive domain expertise, we have identified and acquired or in-licensed a portfolio of development-stage proprietary compounds with innovative mechanisms of action.

DJS Antibodies is developing novel therapeutics to treat chronic inflammatory diseases. DJS does this through the discovery and development of novel therapeutic monoclonal antibodies against GPCRs. The company's breakthrough technology enables its to produce first-in-class antibody therapeutics to previously intractable disease targets.

ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device.  Data in their publications demonstrate that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.

CartiHeal, a privately held medical device company headquartered in Israel, is a pioneer in the field of cartilage regeneration. Cartilage injuries affect millions of patients around the world, and characteristically cause severe pain and disability. Hyaline cartilage has a very limited ability to heal once damaged. Research indicates that injuries to joint cartilage, if left untreated, may lead to progressive joint changes and early onset of osteoarthritis. The need for a simple, well-tolerated and effective solution for cartilage repair and regeneration represents one of medicine’s most challenging unmet needs. CartiHeal's flagship Agili-C™ implant represents a significant medical breakthrough. This implant has shown to promote regeneration of true hyaline cartilage and its subchondral bone, simultaneously without the use of cells, growth factors or other exogenous agents. The cell-free implant is inserted arthroscopically or via a minimally-invasive approach.

Johnson & Johnson Innovation is a center for science and business experts to collaborate with innovators to incorporate science into healthcare solutions, including medical device and diagnostic technologies, consumer healthcare products, and pharmaceuticals. It is focused on the advancement of new healthcare solutions in the consumer, pharmaceutical, and medical devices and diagnostics sectors.’ The company provides financing tools that include early-stage research funding, seed funding, equity investments, licensing, and collaborations. Additionally, it offers its partners access to international markets, pricing and reimbursement, market testing, company creation services, and more. They conduct their activities with the help of regional incubators, satellite operations, single bench tops, modular labs, office space for entrepreneurs, and a year-round curriculum focused on business and drug development. Johnson & Johnson Innovation is a subsidiary of [Johnson & Johnson](http://www.crunchbase.com/organization/johnson-johnson)  and its centers are located in Boston, California, London, and Shanghai.

Johnson & Johnson Robotics and Digital Solutions

Portfolio

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless